Dyne Therapeutics, Inc. 4

David Charles Lubner received an equity compensation grant of 35,152 stock options for Dyne Therapeutics, Inc. common stock at a $17.04 exercise price.

On June 5, 2026, insider David Charles Lubner received a grant of stock options to purchase 35,152 shares of Dyne Therapeutics, Inc. common stock at an exercise price of $17.04 per share, with the options vesting in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholders meeting, contingent on continued service; this equity award increased his derivative holdings but did not involve an immediate cash outlay or open-market trade.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001193125-26-264025

Alert Tier

5